Acumen Pharmaceuticals, Inc.

NasdaqGS:ABOS Stock Report

Market Cap: US$197.9m

Acumen Pharmaceuticals Management

Management criteria checks 4/4

Acumen Pharmaceuticals' CEO is Dan O'Connell, appointed in Dec 2014, has a tenure of 11.58 years. total yearly compensation is $1.86M, comprised of 34.7% salary and 65.3% bonuses, including company stock and options. directly owns 0.41% of the company’s shares, worth $815.26K. The average tenure of the management team and the board of directors is 4.7 years and 6.7 years respectively.

Key information

Dan O'Connell

Chief executive officer

US$1.9m

Total compensation

CEO salary percentage34.68%
CEO tenure11.6yrs
CEO ownership0.4%
Management average tenure4.7yrs
Board average tenure6.7yrs

Recent management updates

Recent updates

New Narrative • Jun 01

Oligomer Antibody And EBD Platform Will Reshape Early Alzheimer’s Treatment Over Time

Catalysts About Acumen Pharmaceuticals Acumen Pharmaceuticals is a clinical stage biotechnology company developing a beta oligomer targeted antibody therapies for Alzheimer's disease. What are the underlying business or industry changes driving this perspective?
New Narrative • May 17

Oligomer Antibody And Brain Delivery Advances Will Reshape Early Alzheimer Treatment Prospects

Catalysts About Acumen Pharmaceuticals Acumen Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing a beta oligomer targeted antibody therapies for Alzheimer’s disease. What are the underlying business or industry changes driving this perspective?
Analysis Article • Aug 05

Does Acumen Pharmaceuticals (NASDAQ:ABOS) Have A Healthy Balance Sheet?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Seeking Alpha • Jul 30

Acumen Pharmaceuticals: Healthy Cash Runway And Market Potential In Alzheimer's

Summary Acumen Pharmaceuticals develops treatments for Alzheimer's disease targeting toxic AβOs, with promising results for sabirnetug in phase 1 clinical trial Intercept-AD. The potential for early AD is approximately 7 million patients, positioning ABOS for significant market share if successful. Sabirnetug’s Phase 1 trial showed promising results, reducing brain amyloid plaques and supporting its mechanism of action for treating early Alzheimer's disease. Acumen Pharmaceuticals has a healthy cash runway, estimated at 3.5 years, and appears undervalued relative to its peers in the biotech sector. Despite the promising data, investing in ABOS is speculative due to the early stages of research and the potential long timeline to FDA approval. Read the full article on Seeking Alpha
Analysis Article • Apr 21

Is Acumen Pharmaceuticals (NASDAQ:ABOS) Weighed On By Its Debt Load?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Sep 21

Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Feb 01

We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Oct 16

Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 28

Acumen Pharma at 11-month high on rivals’ Alzheimer’s data

The shares of microcap biotech Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) more than doubled in value on Wednesday after its rivals Biogen (BIIB) and Eisai (OTCPK:ESALF) (OTCPK:ESALY) announced promising late-stage data for experimental Alzheimer's therapy, lecanemab. In the trial involving nearly 1,800 patients, the amyloid targeting monoclonal antibody cut the cognitive and functional decline in the early stage of Alzheimer's by 27%, compared to placebo, the companies announced late Tuesday. With data validating the amyloid hypothesis in Alzheimer's, developers with similar drugs in their pipeline surged in value. Acumen (ABOS) is advancing its only drug candidate, ACU193 for Alzheimer's, with topline data from a Phase 1 trial expected in H1 2023. ACU193 is a humanized monoclonal antibody that selectively targets amyloid-beta oligomers, which, according to the company, are the most toxic and pathogenic form of amyloid-beta.
Seeking Alpha • Jun 30

Acumen Pharmaceuticals initiated at buy at H.C. Wainwright on Alzheimer's candidate

H.C. Wainwright has initiated Acumen Pharmaceuticals (NASDAQ:ABOS) with a buy rating saying the biopharma's early-stage Alzheimer's candidate, ACU193, has promise. The firm has a $15 price target (~207% return based on Wednesday's closing price). Unlike many other Alzheimer's therapies in development -- and marketed ones such as Biogen's (BIIB) Aduhelm (aducanumab) -- that target the removal of beta amyloid plaque from the brain, ACU193 works differently as a anti-amyloid-beta oligomer (AβO) monoclonal antibody. Analyst Andrew Fein noted that ACU193 "lacks the inflammatory effector functions of other [immunoglobulin] subclasses, thereby making it less prone to [amyloid-related imaging abnormalities], a major safety issue with current anti-[amyloid beta] therapies. Acumen (ABOS) said ACU193 prevents toxic AβOs from binding to dendritic spines and preserves neural function. The company added the candidate has the potential for disease slowing as well as cognitive improvement. The ongoing phase 1 trial is expected to enroll 62 subjects with mild cognitive impairment or mild dementia.
Analysis Article • May 10

We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Jan 07

We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Oct 01

Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

CEO Compensation Analysis

How has Dan O'Connell's remuneration changed compared to Acumen Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$113m

Dec 31 2025US$2mUS$646k

-US$121m

Sep 30 2025n/an/a

-US$133m

Jun 30 2025n/an/a

-US$137m

Mar 31 2025n/an/a

-US$116m

Dec 31 2024US$5mUS$621k

-US$102m

Sep 30 2024n/an/a

-US$82m

Jun 30 2024n/an/a

-US$65m

Mar 31 2024n/an/a

-US$56m

Dec 31 2023US$4mUS$598k

-US$52m

Sep 30 2023n/an/a

-US$49m

Jun 30 2023n/an/a

-US$46m

Mar 31 2023n/an/a

-US$45m

Dec 31 2022US$3mUS$570k

-US$43m

Sep 30 2022n/an/a

-US$38m

Jun 30 2022n/an/a

-US$32m

Mar 31 2022n/an/a

-US$83m

Dec 31 2021US$1mUS$525k

-US$101m

Sep 30 2021n/an/a

-US$93m

Jun 30 2021n/an/a

-US$92m

Mar 31 2021n/an/a

-US$32m

Dec 31 2020US$336kUS$240k

-US$7m

Compensation vs Market: Dan's total compensation ($USD1.86M) is about average for companies of similar size in the US market ($USD1.64M).

Compensation vs Earnings: Dan's compensation has been consistent with company performance over the past year.

CEO

Dan O'Connell (56 yo)

11.6yrs
Tenure
US$1,863,567
Compensation

Mr. Daniel J. O’Connell, also known as Dan, MBA was a Key Advisor at Acidophil, LLC. He served as President until February 01, 2024 and serves as Chief Executive Officer of Acumen Pharmaceuticals, Inc. sin...

Leadership Team

NamePositionTenureCompensationOwnership
Daniel O'Connell
CEO & Director11.6yrsUS$1.86m0.41%
$ 815.3k
James Doherty
President & Chief Development Officer2.4yrsUS$1.01m0.017%
$ 34.4k
Matt Zuga
CFO & Chief Business Officer5.2yrsUS$948.79k0.17%
$ 345.0k
Grant Krafft
Co-Founder30.5yrsUS$42.00kno data
Caleb Finch
Co-Founderno datano datano data
William Klein
Co-Founderno datano datano data
Russell Barton
Chief Operating Officer5.5yrsUS$223.68k0.087%
$ 172.5k
Kelly Carranza
Senior Vice President of Finance & Accounting and Corporate Controller3yrsno datano data
Alex Braun
VP & Head of Investor Relations3.8yrsno datano data
Derek Meisner
Chief Legal Officer & Corporate Secretary3.8yrsUS$1.48m0%
$ 0
Robyn Moxon
Associate Director of Communications4.2yrsno datano data
Julie Bockenstette
Chief People Officer5.5yrsno datano data
4.7yrs
Average Tenure
57yo
Average Age

Experienced Management: ABOS's management team is considered experienced (4.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Daniel O'Connell
CEO & Director20.3yrsUS$1.86m0.41%
$ 815.3k
Michael Weiner
Member of Clinical & Scientific Advisory Boardno datano datano data
Colin Masters
Member of Clinical & Scientific Advisory Boardno datano datano data
Jeffrey Cummings
Member of Clinical & Scientific Advisory Boardno datano datano data
Sean Stalfort
Independent Director7.8yrsUS$107.05k0.44%
$ 867.8k
Kimberlee Drapkin
Independent Director4.3yrsUS$89.11k0.018%
$ 35.1k
Steven DeKosky
Member of Clinical & Scientific Advisory Boardno datano datano data
Jeffrey L. Ives
Independent Director12.2yrsUS$79.11k0.018%
$ 35.1k
Cynthia Lemere
Member of Clinical & Scientific Advisory Boardno datano datano data
George Golumbeski
Independent Chairman of the Boardless than a yearUS$82.74k0%
$ 0
Laura Stoppel
Independent Director5.7yrsUS$84.61k0.018%
$ 35.1k
Stephen P. Salloway
Member of Clinical & Scientific Advisory Boardno datano datano data
6.7yrs
Average Tenure
69yo
Average Age

Experienced Board: ABOS's board of directors are considered experienced (6.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 00:53
End of Day Share Price 2026/07/06 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Acumen Pharmaceuticals, Inc. is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason ZemanskyBofA Global Research
Thomas ShraderBTIG
Pete StavropoulosCantor Fitzgerald & Co.